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ABSTRACT A recent randomized controlled trial, the WANECAM (West African
Network for Clinical Trials of Antimalarial Drugs) trial, conducted at seven centers in
West Africa, found that artemether-lumefantrine, artesunate-amodiaquine, pyronari-
dine-artesunate, and dihydroartemisinin-piperaquine all displayed good efficacy.
However, artemether-lumefantrine was associated with a shorter interval between
clinical episodes than the other regimens. In a further comparison of these therapies,
we identified cases of persisting submicroscopic parasitemia by quantitative PCR
(qPCR) at 72 h posttreatment among WANECAM participants from 5 sites in Mali
and Burkina Faso, and we compared treatment outcomes for this group to those
with complete parasite clearance by 72 h. Among 552 evaluable patients, 17.7% had
qPCR-detectable parasitemia at 72 h during their first treatment episode. This pro-
portion varied among sites, reflecting differences in malaria transmission intensity,
but did not differ among pooled drug treatment groups. However, patients who
received artemether-lumefantrine and were qPCR positive at 72 h were significantly
more likely to have microscopically detectable recurrent Plasmodium falciparum para-
sitemia by day 42 than those receiving other regimens and experienced, on average,
a shorter interval before the next clinical episode. Haplotypes of pfcrt and pfmdr1
were also evaluated in persisting parasites. These data identify a possible threat to
the parasitological efficacy of artemether-lumefantrine in West Africa, over a decade
since it was first introduced on a large scale.
KEYWORDS Plasmodium falciparum, antimalarial agents
The antimalarial efficacy of artemisinin-based combination therapies (ACT) againstPlasmodium falciparum infections in Africa remains high, with .90% efficacy for all
current regimens (1). Despite this generally positive picture, evidence is growing that
parasites with reduced susceptibility do occur across the continent. In the latest World
Malaria Report, the WHO notes four studies in Malawi, Angola, Uganda, and The
Gambia in which more than 10% of malaria patients treated with the widely deployed
ACT artemether-lumefantrine (AL) failed treatment (2). Similar indications were evident
in recent clinical trials. The multicenter WANECAM (West African Network for Clinical
Trials of Antimalarial Drugs) study treated 4,710 individuals for clinical malaria in
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Burkina Faso, Guinea, and Mali and followed them for 2 years, finding that both estab-
lished and recently licensed ACT provided PCR-corrected adequate clinical and parasi-
tological response (ACPR) against Plasmodium falciparum malaria in all 7 study sites (3).
However, AL did not perform as well as either of the newer formulations pyronaridine-
artesunate (PA) and dihydroartemisinin-piperaquine (DP) as indicated by, first, lower ef-
ficacy (uncorrected) at 28 and 42 days after treatment and, second, a shorter time to
next malaria episode than in patients randomized to receive either DP or PA. Both
observations may be attributable to the shorter elimination half-life of lumefantrine
(4 days) than of pyronaridine (13 days) and piperaquine (4 weeks) (1). Nevertheless,
posttreatment parasite isolates from a subset of AL-treated Malian patients in the
WANECAM cohort demonstrated a higher 50% effective concentration (EC50) than did
pretreatment isolates for both artemether and lumefantrine in ex vivo susceptibility
testing (4), suggesting a waning parasite susceptibility to AL consistent with other find-
ings in West Africa (5, 6). Relevant findings also come from the other side of the conti-
nent; our Kenyan studies found that subpatent parasite persistence in AL- and DP-
treated patients was strongly linked to subsequent microscopically detectable parasite
recrudescence 4 to 6weeks later (7) and found significant selection for an Asn substitu-
tion at codon 86 of pfmdr1 (8), the locus encoding the parasite digestive vacuole (DV)
membrane transporter PgH1. Further, recent studies of imported P. falciparum malaria
cases in Sweden and the United Kingdom document cases of AL treatment failure in
parasites of African origin (9, 10). Therefore, there is an urgent need to examine the ef-
ficacy of AL in African settings and test for association with resistance-associated
markers in order to inform molecular surveillance efforts.
The determinants of parasite susceptibility to lumefantrine remain unclear, and in
vitro correlates of susceptibility are not yet well established. Cultured parasite isolates
from patients that have failed AL treatment display little difference in standard lume-
fantrine EC50 estimates from those of isolates from successfully treated patients (11).
However, it has been established that the wild-type codon 86 Asn (N) allele in pfmdr1
has a strong selective advantage over the chloroquine-selected 86 Tyr (Y) mutation,
with 86N showing significant directional selection in a number of African studies of AL-
treated malaria patients (8, 12–14). A statistically significant increase in lumefantrine
EC50 is also seen when the 86N allele replaces the Y allele in gene-editing experiments
in chloroquine-resistant lab-adapted parasite strains (15). Nevertheless, there is as yet
no compelling evidence that this change in pfmdr1 alone is sufficient to engender full-
blown lumefantrine resistance in vivo, and there are compelling reasons to believe that
AL also exerts selective pressure on the pfcrt locus (8), which encodes another trans-
porter protein in the parasite digestive vacuole membrane and is the key determinant
of chloroquine and amodiaquine susceptibility (16, 17).
Over the last decade, a clearer picture of the key determinants of susceptibility to
the artemisinin component of ACT has emerged, relevant to the emergence in
Southeast Asia of P. falciparum harboring certain variants of the Kelch propeller do-
main protein K13, encoded by the pfk13 gene. Patients infected with these parasites
display slower parasite clearance after treatment with either artemisinin monotherapy
or ACT (18–21), and in vitro correlates have been developed which demonstrated that
any one of these specific mutations is both necessary and sufficient to enhance para-
site survival against a short pulse of high-dose artemisinin in vitro (22, 23). Surveillance
of pfk13 genotypes across Africa has been carried out since the identification of this re-
sistance-associated locus, but to date, the key mutations associated with reduced arte-
misinin susceptibility in Southeast Asia have been absent in population surveys
(24–27) and in sequence analyses of African parasite isolates from patients who failed
treatment with AL (5, 6, 28). Recently, a focus of P. falciparum harboring the R561H pro-
peller domain variant of pfk13 was identified in Rwanda (29). This genotype was associ-
ated with both slow parasite clearance and parasitological treatment failure at day 28.
Further work is required to ascertain whether these parasites represent a growing
threat to the clinical efficacy of AL in east Africa.
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Evaluation of clinical efficacy in antimalarial drug trials would be greatly advanced
by efficient and sensitive quantitative molecular methods to establish posttreatment
parasite clearance dynamics and to detect parasites persisting during the posttreat-
ment follow-up period. In this study, we deployed quantitative PCR (qPCR) amplifica-
tion of parasite DNA from the WANECAM study. PCR-corrected drug efficacy findings
for this study of 4,710 ACT-treated participants, carried out between October 2011 and
December 2013, have been previously published (3). We present new parasite clear-
ance data for a subset of 552 participants to explicitly explore the relationship between
parasite persistence in the first 72 h following initiation of treatment and three out-
comes from the main study: (i) uncorrected ACPR during 42 days of active follow-up,
(ii) time to the next episode of symptomatic malaria over 2 years of passive follow-up,
and (iii) microscopic gametocyte carriage at day 7.
In patients with persisting submicroscopic parasites at day 3, we also tested for evi-
dence of directional selection at the pfcrt and pfmdr1 loci.
RESULTS
Baseline information for all 552 individuals analyzed, including treatment group in
the parent randomized trial, is given in Table 1. Of these, 280 experienced a second
malaria episode; blood samples at all four time points were available for 276. These
second episodes occurred a median of 89 days after episode 1 (interquartile range,
60 to 201 days) among the 241 individuals for which both dates were available. Equal
numbers of participants evaluated in this subanalysis received the two investigational
regimens PA and DP (178 and 177, respectively). These were compared to standard
ACT for the site concerned: 126 participants received AL and 71 received artesunate-
amodiaquine (ASAQ), which was used in two sites only (Table 1). For the following
analyses, individuals in the ASAQ treatment arm contributed to each combined analy-
sis but were not included in stratified statistical tests, as participants were not random-
ized between the AL and ASAQ regimens (1).
Parasite clearance dynamics in the first 72h of treatment. Extracted DNA from
all time points up to day 3 was analyzed by duplex qPCR, with each time point run
twice. A total of 405 treated participants at episode 1 were qPCR negative by day 2
(73.4%), and a further 64 participants displayed a relative parasite density between 0
and 0.1% of that on day 0; all 469 met the criteria for good clearance (parasite reduc-
tion rate at 48 h [PRR48h] estimate of 1,000 or greater). For the remaining 83 infections
classed as slow clearing for episode 1 (15.0%), day 2 parasite density ranged from
0.11% to 92.1% of day 0 parasite density (median, 0.69%; interquartile range, 0.21% to
2.8% of day 0 parasite density). Thirty-eight of 276 evaluable infections in episode 2
were slow clearing (13.8%), with day 2 parasite density ranging from 0.11% to 155.8%
of day 0 density (median, 0.56%; interquartile range, 0.28% to 3.68%).
Two binary parasite clearance parameters were derived from the analysis: slow clear-
ance, defined as PRR48h of less than 1,000, and day 3 qPCR positivity. Within patient groups
defined by treatment arm and study site, there was no general pattern of correlation
TABLE 1 Baseline information for all 552 patients contributing to the analysis
Site






femalePA (n=172) AL (n =121) DP (n=176) ASAQ (n=71)
Sotuba (n=128) 27.3 47.7 25.0 6.2 39.7 22.7
Kolle (n= 105) 33.3 33.3 33.3 14.3 78.1 43.8
Bougoula Hameau (n= 105) 31.4 34.3 34.3 10.1 82.7 53.7
Ninagoloko (n = 105) 33.3 33.3 33.3 19.8 32.1 55.3
Bobo-Dioulasso (n=109) 36.7 27.5 35.8 19.3 25.9 52.9
ACPR (%) (uncorrected) 87.8 80.1 97.2 76.6
aPA and DP, the investigational regimens, were tested in all sites against either one of the two comparator regimens, AL and ASAQ (artesunate-amodiaquine).
bEpisode 2 is a subsequent clinical malaria episode diagnosed at least 28 days after the primary episode in the same individual. A total of 280 individuals in the analysis
experienced a second episode. The same study drug was always given (1). Study site staff decided which individuals to include in this analysis; it was not a random
selection, and therefore, the proportion of 2nd episodes in each site has no epidemiological significance.
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between episode 1 and episode 2 in either clearance parameter; data for day 3 qPCR positivity
in both episodes are presented in Fig. 1. For episode 1, parasitemia was cleared more slowly
(i.e., PRR48h was more often below 1,000) with AL than with PA or DP among patients
recruited at Kolle (odds ratio [OR], 4.5, 95% confidence interval [CI], 1.20 to 18.50; P=0.008),
but this difference was not seen among those recruited at Sotuba or Bobo Dioulasso.
Similarly, only in Kolle was there a substantially higher prevalence of qPCR-positive day 3
parasitemia in the AL group than in the PA and DP groups (OR, 6.75; 95% CI, 2.18 to 22.1;
P, 0.001). In paired analyses on an individual level, slow clearance in episode 1 was not
associated with a higher chance of slow clearance occurring in episode 2 (OR, 0.850; 95% CI,
0.243 to 2.40; P=0.75), and being qPCR positive on day 3 in episode 1 was not associated
with a higher chance of being qPCR positive on day 3 in episode 2 (OR, 0.674; 95% CI, 0.240
to 1.65; P=0.369).
The detection of persistent parasite carriage over the first 72 h posttreatment could
plausibly be associated with higher parasite densities at enrollment, which may take
longer to clear. We therefore compared parasite densities by microscopy (as previously
reported [3]) for individuals found to be qPCR positive at day 3 with those from individ-
uals that were qPCR negative at day 3. Among all 470 evaluable individuals with epi-
sode 1 parasite density available, those found to be qPCR positive at day 3 displayed
higher day 0 parasite densities (P=0.002; Wilcoxon rank sum test). However, after strat-
ification by treatment arm, this relationship was maintained for ASAQ (P=0.039;
n=53) and PA (P= 0.042; n =152) but not for AL (P=0.175; n =124) or DP (P=0.570;
n=141).
Parasite genotypes in day 3 positives. Previous studies suggest that ACT, and
artemisinin in particular, selects against the pfmdr1 86 Tyr and pfcrt 72 to 76 CVIET
genotypes that had previously been favored by the use of chloroquine (4, 8, 12–15).
The prevalence of the corresponding wild-type alleles pfmdr1 86 Asn and pfcrt 72 to 76
CVMNK are shown in Fig. 2, for each study site, at day 0 and day 3 of episode 1. pfcrt
genotyping was successful in 40.2% of qPCR positives from the parasite clearance data
and in 22.9% of the negatives. pfmdr1 sequencing was successful in 47.4% of the posi-
tives and 19.0% of the negatives. Pretreatment prevalence of CVMNK varied among
the 5 sites but appeared to increase in prevalence in most sites at day 3 (Fig. 2, upper
graph). pfmdr1 86 Asn was at 80% or higher prevalence at day 0 in all sites, and
increases (4 sites) or decreases (1 site) by day 3 were small (Fig. 2, lower graph). As an
FIG 1 Proportion of participants qPCR positive at day 3 for episodes 1 and 2. Colored bars represent
proportion of slow-clearing P. falciparum infections for each of the 4 treatment groups in the primary
malaria episode, and inlaid white bars represent proportion for episode 2 in the same patient group.
Denominators are given for episode 1 and episode 2.
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exploratory paired analysis, we tested the full day 3 data set for evidence of selection
against CVIET and pfmdr1 86 Tyr within each individual infection. Perhaps reflecting
the already low prevalence at day 0, there was no evidence of significant directional
selection against pfmdr1 86Tyr (n=149; P=0.086), but in contrast, we did find evidence
of directional selection against pfcrt 72 to 76 CVIET (n=137; P= 0.008).
Association between parasite clearance and treatment outcome. The first of
two primary outcome measures in the main clinical study was the incidence density of
malaria episodes over 2 years of follow-up. We therefore tested for evidence that slow
clearance or day 3 qPCR positivity after treatment for episode 1 was associated with a
shorter interval between episode 1 and episode 2 among the 280 individuals for
whom we had paired assessments. The distribution of recorded times between epi-
sode 1 and episode 2 was found to fail the Shapiro-Wilks test for normality both with
and without lognormal transformation, so nonparametric methods were used to evalu-
ate association with this variable. By the Wilcoxon rank sum test, weak evidence was
found across all 233 evaluable individuals that a shorter interval to episode 2 was asso-
ciated with qPCR day 3 positivity but was not associated with slow clearance, defined
as PRR48h below 1,000 (Table 2). Stratifying by treatment arm, we found that the associ-
ation between qPCR day 3 positivity and shorter interval to episode 2 was entirely resi-
dent in the AL-treated participants and was not found among participants treated with
PA or DP (Table 2).
The second primary outcome of the parent clinical trial that we examined was
uncorrected ACPR over 28 or 42 days of follow-up (1). We therefore tested for evidence
FIG 2 Prevalence of pfcrt CVMNK and pfmdr1 codon 86Asn alleles among day 0 and day 3 isolates by
study site. Denominators shown are for day 0 and day 3.
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that slow clearance or day 3 qPCR positivity was associated with treatment failure (i.e.,
recurrent parasitemia by microscopy) on or before day of episode 1 among 536 evalu-
able participants. In the combined data set, slow clearance (i.e., PRR48h of ,1,000 by
qPCR) was not a risk factor for subsequent treatment failure among these participants;
in contrast, qPCR positivity at day 3 was significantly associated with treatment failure
on or before day 42 (Table 2). When this analysis was stratified by treatment group, fail-
ure to reach ACPR at day 42 was strongly associated with qPCR positivity at day 3 in
the AL-treated group but was not associated in the PA-treated group or the DP-treated
group (Table 2).
Finally, we examined the relationship between slow clearance and qPCR positivity at
day 3 and microscopically detected P. falciparum gametocytes at day 7, as in our previ-
ous Kenyan studies (3). Evidence of an association between slow clearance and gameto-
cyte carriage was found among all evaluable individuals. Interestingly, after stratification,
this association was strong among PA-treated participants and borderline nonsignificant
among DP-treated individuals but absent in the AL-treated group (Table 2). There was
no association between day 7 gametocyte carriage and qPCR positivity at day 3.
Factors affecting the association between day 3 positivity and ACPR. The analy-
ses presented in Table 2 suggest a relationship between qPCR positivity at day 3 and
treatment failure, defined as not exhibiting ACPR by day 42. However, there are a num-
ber of potential confounders generally accepted as affecting the likelihood of ACPR,
the principal example being patient age. Other key covariates that may impact this
association include initial parasite density, sex, study site, and treatment arm. To exam-
ine the impact of these factors on the OR of the association between qPCR positivity
on day 3 and day 42 ACPR, we used logistic regression. As shown in Table 3, the OR of
2.70 (1.24 to 5.58) from Table 2 fell to 2.11 but remained significant in a simple model
including only patient age. When age, log-transformed parasite density, sex, study site,
and treatment arm are all included in the model, there is little further change in the
OR, with the association remaining significant and no increase in standard error of the
estimate. We conclude that our finding of an association between qPCR positivity at
day 3 and treatment failure remains robust after correction for potential confounding
by age, parasite density, sex, study site, and treatment arm.
DISCUSSION
In this study, we used qPCR to estimate two parameters related to parasite clear-
ance dynamics in over 800 episodes of falciparum malaria experienced by 552 study
TABLE 2 Univariate associations between parasite clearance and treatment outcomesa
Parameter Treatment arm Shorter time to E2b
OR (95% CI) for E1 day 42
ACPR not achieved
OR (95% CI) for
gametocytes at day 7
Slow clearance (PRR48h , 1,000) All combinedc 83 days vs 91 days (n=241;
P= 0.484)






AL 0.0 (n=124; P=0.660)
DP 4.7 (0.365–43.9)
(n=143; P=0.073)
qPCR positive day 3 All combinedc 66 vs 95days (n=45,
188; P=0.0032)












DP 133 vs 98 days (n= 7, 63;
P= 0.899)
0.0 (0.0–7.17) (n= 174;
P= 0.453)
aE1, treated clinical malaria episode 1; E2, treated clinical malaria episode 2.
bMeasured in days; for significant differences (bold), median number of days is shown for the 2 groups. Accurate dates for E2 were not available for some individuals;
ASAQ-treated individuals (n=29) were retained in the combined analysis but are not shown in the stratification.
cStratification by treatment arm is presented only where an effect was seen in the combined analysis. Stratified analysis for ASAQ-treated patients (n=29) is not shown.
Beshir et al. Antimicrobial Agents and Chemotherapy













































participants treated with ACT in Mali and Burkina Faso. In particular, we sought evi-
dence that AL was inferior to DP or PA in initial clearance of parasitemia up to day 3
and whether this was associated with three key outcomes: time to next malaria epi-
sode, uncorrected ACPR at day 42, and microscopically detectable gametocyte carriage
at day 7. In one site, Kolle, there was some evidence that slow clearance of parasitemia
and qPCR positivity at day 3 was higher in the AL-treated group than for PA or DP, but
this was seen only for episode 1, as parasite clearances were similar for PA and AL
among the 82 second episodes from Kolle in our sample set and only slightly better for
DP (Fig. 1 and 2). However, parasite clearance did have an impact on outcomes, as
those that were qPCR positive at day 3 experienced a significantly shorter period
before a subsequent malaria episode (a median of 66 versus 95 days) and were more
likely to fail treatment by day 42, as evidenced by microscopically detected parasitemia
during study follow-up. After stratification, both of these associations remained signifi-
cant only in the AL-treated group. Gametocyte carriage at day 7 was weakly associated
with slow clearance, but AL performed better than PA or DP. We conclude that in the
PA and DP treatment groups, qPCR-detected parasite persistence immediately after
treatment was related to gametocyte emergence in many instances, whereas in the
group treated with AL, which has an impact on gametocyte carriage superior to those
of other ACT (1, 3, 30, 31), parasite persistence was more likely indicative of persisting
asexual parasitemia. We also show that in settings where the chloroquine-resistant al-
leles of pfcrt are still present (Fig. 2), artemisinin treatment can exert directional selec-
tion toward the chloroquine-sensitive allele CVMNK at codons 72 to 76, detectable as
early as day 3. This supports our previous findings in Kenya (8). Future studies should
deploy this approach to test for selection on other marker genes of interest, including
pfk13, pfcoronin, pfubp1, and pfap2mu (32).
In the context of Africa, where many participants in clinical malaria studies are chil-
dren, the utilization of filter paper DNA sampling of finger prick blood taken once daily
for the first 3 days of antimalarial treatment is an attractive alternative to frequent (every
6 to 12 h) sampling for microscopy as used for clinical studies of artemisinin efficacy in
the Mekong region (7, 18, 19, 21). Although the relatively sparse sampling density makes
it more difficult to estimate the slope of the clearance curve accurately, in our hands day
3 qPCR positivity has now proved to be a useful measure of persistent parasitemia, im-
mediately posttreatment, in unrelated studies in Kenya (8), Indonesia (33) and now the
West African Sahel. In particular, the relationship between detection of Plasmodium DNA
at day 3 and subsequent microscopically detectable asexual parasite recurrence in both
African studies suggests that our definitions of treatment success and treatment failure
need to be reconsidered. The advent of sensitive and precise methods for parasite DNA
measurement and quantitation is an opportunity to set a higher bar for treatment suc-
cess; indeed, it is ironic that whereas DNA amplification methods have been wholly
embraced by the malaria research field for determination of PCR-corrected estimates of
TABLE 3 Logistic regression of potential confounding factors for the association between







arm OR (95% CI) SE P
1 (n= 536) 2.70 (1.53–4.76) 0.782 0.001
2 (n =476a) X 2.11 (1.11–4.03) 0.695 0.023
3 (n =464b) X 2.05 (1.08–3.90) 0.674 0.013
4 (n =464) X X 1.95 (1.01–3.73) 0.646 0.045
5 (n =464) X X X 1.98 (1.03–3.80) 0.659 0.041
6 (n= 464) X X X X 2.02 (1.05–3.89) 0.676 0.035
7 (n= 464) X X X X 1.97 (1.03–3.80) 0.659 0.042
8 (n= 464) X X X X X 2.02 (1.05–3.89) 0.675 0.036
aAge data were missing for 60 individuals.
bRegression was performed against log-transformed microscopy-determined parasite densities (1). Day 0
parasite density was missing for 62 individuals.
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clinical drug efficacy (34, 35), parasite DNA detection has not been embraced as a pri-
mary endpoint in itself. In the current decade, when elimination of malaria remains a
firm objective in many settings, we suggest that recurrent parasitemia identified by
nucleic acid amplification tests (NAAT) in the follow-up of antimalarial drug trials should
be explored as a primary endpoint in treatment trials, particularly in low-transmission
settings and those approaching elimination. NAAT are well-established as endpoints in
vaccine and drug studies using controlled human malaria infections in volunteers (36,
37) and require only a little further work to be field deployable. An additional benefit is
the availability of these DNA samples for concurrent analysis of markers of parasite sus-
ceptibility, as demonstrated here for pfcrt and pfmdr1.
There are a number of aspects of our study that may reduce the generalizability of
our findings. Most importantly, the subjects of the work described here are a subset of
552 from a larger study of 4,710 individuals (1). These were not randomly selected but
rather were a convenience sample from each of the 5 participating sites, selected on the
basis of having a full filter paper set available for each of approximately 105 individuals
from each site, within externally imposed time restrictions as to the availability of labora-
tory capacity in London for Malian and Burkinabe personnel to visit and undertake train-
ing in DNA extraction and qPCR, followed by the analysis. Therefore, caution is war-
ranted before generalizing these results to the full study, to the wider West African
context, or to the continent in general. Further, there do seem to be differences between
sites in the age distributions and the gender ratios (Table 1). More importantly, in one
site, Sotuba, a much smaller proportion of individuals with a full set of episode 2 blood
samples was included in the analysis, reducing generalizability of our findings regarding
time to episode 2. This is probably due to differences in approach to selection of the
sample for each local research team. This analysis was not among the primary or second-
ary outcomes of the main trial, and few resources were available in the field to supervise
this aspect. Future studies should seek to perform this analysis for all randomized partici-
pants, in order to overcome this problem of potential selection bias, and to clearly set
out in the primary protocol all aspects of the procedure.
By current accepted definitions, Sagara and colleagues found AL to have acceptable ef-
ficacy in the parent study and that the investigational regimens PA and DP were noninfe-
rior and with a good safety profile when tested in a retreatment design over 2 years of fol-
low-up (3). Nevertheless, as discussed in the introduction, these authors presented ample
evidence to suggest that these regimens were actually superior to AL in a number of
aspects, including ACPR without PCR correction (Fig. 2 in reference 1). As we have pro-
vided evidence of a link between qPCR-detectable parasitemia at day 3 and uncorrected
ACPR in the AL treatment group, suggesting that persistent parasites in some participants
were misclassified by the PCR correction methodology used in WANECAM (1), this may be
an important indication that in vivo parasite susceptibility to AL is waning in Africa. Our
Kenyan studies (7, 8) and identification of treatment failures among AL-treated European
travelers add further weight to this interpretation (9, 10). Only a few reports from the field
indicate unsatisfactory effectiveness of AL in the African context (5, 6). This could mean
that the problem is not yet of public health significance or that in settings with a high pro-
portion of malaria infections occurring in people with some level of previously acquired
antiparasite immunity, treatment failure is less easy to identify. Our current data do pro-
vide some comfort in this regard: slow clearance in episode 1 was not associated with
poor treatment outcomes in episode 2, suggesting that patients were not harboring stub-
bornly drug-resistant parasite populations that persisted until the subsequent episode.
Important questions remain, and we recommend that careful investigations of ACT effi-
cacy using nucleic acid detection as an endpoint be prioritized, at least in low-transmission
and/or pre-elimination settings. In addition, a simple surveillance protocol based on a few
well-timed finger prick samples linked to national or regional laboratories equipped for
DNA extraction and qPCR detection of parasitemia should be on the agenda as a replace-
ment for the current workhorse of blood film microscopy, which nevertheless retains its
usefulness for primary diagnosis in African health systems.
Beshir et al. Antimicrobial Agents and Chemotherapy













































In conclusion, the combination of a simple daily finger prick sampling regimen and a
well-established qPCR method for measuring parasite clearance dynamics, which is readily
transferable (38), has permitted us to show that a relationship exists between persisting
submicroscopic parasitemia at day 3 after ACT and microscopically detected treatment fail-
ure by day 42. This suggests that the efficacy of AL in particular may be under threat in
West Africa, after 10 to 15years of deployment, and that nucleic acid testing methods may
provide a more effective definition of endpoints in future studies of drug efficacy.
MATERIALS ANDMETHODS
Clinical trial design and registration. This work was performed as an exploratory analysis, defined
in the main protocol, of the WANECAM study (1). Trial design, registration, and regulatory approvals are
as described therein.
Patients and study sites. Research staff at each of three sites in Mali—Sotuba, Kolle, and Bougoula
Hameau—and two in Burkina Faso—Niangoloko and Bobo Dioulasso—identified a group of at least 100
WANECAM study participants for which filter paper blood spots were available from each of day 0 (pre-
treatment) and day 1, day 2, and day 3 of posttreatment follow-up for the primary episode of falciparum
malaria that led to the inclusion of the individual in the study. Blood samples taken at day 0, day 1, day
2, and day 3 from individuals with a second episode occurring 28 days or more after the primary malaria
episode were also included in the analysis if available.
qPCR analysis of parasite clearance. DNA was extracted from filter paper blood samples from each
individual using a modification of the Chelex method (39, 40). Parasite DNA at days 0, 1, 2, and 3 was
detected using qPCR, and relative parasite density was estimated by amplification of pgmet (a genus-
specific target) normalized to the human b-tubulin gene humtubb as previously described (41). qPCR
was performed in duplicate on a Rotor-gene Q thermocycler (Qiagen, Germany). Results were expressed
as the parasite reduction rate at 48 h (PRR48h) and by the binary outcome positive or negative by qPCR
on day 3. This method has now been successfully deployed in a number of field studies in Africa and
Asia and has an estimated limit of detection of 0.05 parasite perml of whole blood (7, 33, 42).
Genotyping of resistance-associated loci. Genotyping of the pfcrt and pfmdr1 genes was carried
out using established methods, with minor modifications. Polymorphisms at codons 72 to 76 in the pfcrt
gene were determined using multiplex qPCR (43). Variants at codon 86 of pfmdr1 were identified by
direct sequencing of PCR products as described previously (13, 14).
Statistical analysis. Odds ratio (OR) and 95% confidence interval were estimated for each test of
association between binary variables, and statistical significance was estimated from the x2 distribution.
To evaluate the contribution of variables to day 42 treatment failure and to the time elapsed before the
next malaria episode, a logistic regression model was built for each outcome, incorporating all variables
found to be significant in univariate analyses, in descending order of OR. Data were tested for normal
distribution using the Shapiro-Wilks test, with and without lognormal transformation. Normally distrib-
uted continuous data were analyzed using Student’s t test and nonnormally distributed data by rank
sum test. Parasite density estimates were log transformed for analysis by the rank sum test or for logistic
regression. In paired samples, evidence of directional selection was tested for statistical significance by
McNemar’s test for symmetry. P values of#0.05 were considered statistically significant.
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